Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-Lung III: ctDNA-Guided Consolidation Chemotherapy and Immunotherapy in Stage III NSCLC
NCT07858253Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2030
01
Overview
A Phase 2 trial of carboplatin, pemetrexed, Paclitaxel Micelles for Injection, durvalumab in non-small cell lung cancer (NSCLC). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
carboplatinpemetrexedPaclitaxel Micelles for Injectiondurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07858253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07858253.